Evaluation of a spray-dried dispersion (SDD) formulation of MGCD265, a receptor tyrosine kinase (RTK) inhibitor, in a phase 1 study of patients (pts) with advanced solid tumors

被引：0
|
作者：
Sharma, Sunil
Shapiro, Geoffrey
Kollmannsberger, Christian K.
Christensen, James
Tassell, Vanessa Roberts
Faltaos, Demiana
Chao, Richard C.
Hurwitz, Herbert
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e14087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14087
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase 1 study of a focal adhesion kinase (FAK) inhibitor PF-00562271 in patients (pts) with advanced solid tumors
    Siu, L. L.
    Burris, H. A.
    Mileshkin, L.
    Camidge, D. R.
    Rischin, D.
    Chen, E. X.
    Jones, S.
    Yin, D.
    Fingert, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors
    Langenberg, M. H. G.
    Witteveen, P. O.
    Roodhart, J.
    Lolkema, M. P.
    Verheul, H. M. W.
    Mergui-Roelvink, M.
    Brendel, E.
    Kratzschmar, J.
    Loembe, B.
    Nol-Boekel, A.
    Christensen, O.
    Schellens, J. H. M.
    Voest, E. E.
    ANNALS OF ONCOLOGY, 2011, 22 (11) : 2508 - 2515
  • [23] Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors
    Daud, Adil I.
    Krishnamurthi, Smitha S.
    Saleh, Mansoor N.
    Gitlitz, Barbara J.
    Borad, Mitesh J.
    Gold, Philip J.
    Chiorean, Elena G.
    Springett, Gregory M.
    Abbas, Richat
    Agarwal, Shefali
    Bardy-Bouxin, Nathalie
    Hsyu, Poe-Hirr
    Leip, Eric
    Turnbull, Kathleen
    Zacharchuk, Charles
    Messersmith, Wells A.
    CLINICAL CANCER RESEARCH, 2012, 18 (04) : 1092 - 1100
  • [24] Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors
    Eckhardt, SG
    Rizzo, J
    Sweeney, KR
    Cropp, G
    Baker, SD
    Kraynak, MA
    Kuhn, JG
    Villalona-Calero, MA
    Hammond, L
    Weiss, G
    Thurman, A
    Smith, L
    Drengler, R
    Eckardt, JR
    Moczygemba, J
    Hannah, AL
    Von Hoff, DD
    Rowinsky, EK
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1095 - 1104
  • [25] A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors
    Sarker, Debashis
    Molife, Rhoda
    Evans, T. R. Jeffrey
    Hardie, Maryon
    Marriott, Cheryl
    Butzberger-Zimmerli, Priska
    Morrison, Rosemary
    Fox, Judith A.
    Heise, Carla
    Louie, Sharianne
    Aziz, Natasha
    Garzon, Felix
    Michelson, Glenn
    Judson, Ian R.
    Jadayel, Dalal
    Braendle, Edgar
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2008, 14 (07) : 2075 - 2081
  • [26] Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
    Kim, Tae Min
    Lee, Keun-Wook
    Oh, Do-Youn
    Lee, Jong-Seok
    Im, Seock-Ah
    Kim, Dong-Wan
    Han, Sae-Won
    Kim, Yu Jung
    Kim, Tae-You
    Kim, Jee Hyun
    Han, Hyesun
    Kim, Woo Ho
    Bang, Yung-Jue
    CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 835 - 842
  • [27] Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors
    Zhou, Qing
    Wu, Yi Long
    Yu, Xiyong
    Yang, Jinji
    Wen, Limin
    Sai, Yang
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors
    Langenberg, Marlies H. G.
    Witteveen, Petronella O.
    Roodhart, Jeanine M.
    Verheul, Henk M. W.
    Mergui-Roelvink, Marja
    van der Sar, Jana
    Brendel, Erich
    Laferriere, Nicole
    Schellens, Jan H. M.
    Voest, Emile E.
    CLINICAL CANCER RESEARCH, 2010, 16 (07) : 2187 - 2197
  • [29] Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in patients with advanced solid tumors;: a vertical blockade of the VEGF pathway
    Langenberg, M. H. G.
    Verheul, H. M. W.
    Witteveen, P. O.
    Lolkema, M.
    Roodhart, J. M. L.
    Nol, A.
    Roelvink, M.
    Brendel, E.
    Kraetzschmar, J.
    Schellens, J. H. M.
    Voest, E. E.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3345S - 3345S
  • [30] Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Yamamoto, Noboru
    Sunami, Kuniko
    Utsumi, Hirofumi
    Asou, Hiroya
    Takahash, Osamu, I
    Ogasawara, Ken
    Gueorguieva, Ivelina
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1143 - 1152
12345